Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Moving Towards a Universal Flu Vaccine

Published: Monday, December 31, 2012
Last Updated: Monday, December 31, 2012
Bookmark and Share
Israeli company reports good results with supplemental shot in elderly.

Multimeric-001, an influenza vaccine now in clinical trials, boosts immunity in elderly people when given as a supplement to the seasonal shot.

But supplementation is just a short-term goal: eventually the drug’s maker, BiondVax Pharmaceuticals of Ness Ziona, Israel, believes that Multimeric-001 alone could protect against all strains of flu.

The company will present the results from its second phase II trial of the shot on 3 April at the Second Annual Vaccines Congress in London.

The 90 people aged 65 and older who got the pair of shots, compared to 30 who received only the annual vaccine, mounted a stronger immune response to the three seasonal flu strains, as well as to a few other strains not in the seasonal vaccine.

For most infectious agents, one exposure teaches the body’s immune system to recognize and destroy the virus or bacterium. The standard flu vaccine teaches the body to recognize the virus's outer coating.

But influenza is constantly changing its stripes, mutating from year to year and forcing scientists to guess which three strains to include in the seasonal vaccine.

“This is crazy,” says Vincent Racaniello, a virologist at Columbia University in New York, who is not involved with the Biondvax trials. If there were one vaccine that worked for any kind of flu, no matter how it mutated its coat, the costs of protection would drop and pandemics could disappear, he says.

The Multimeric-001 vaccine comprises nine linked sections from three flu proteins from different parts of the virus. These represent a “common denominator” shared by more than 10,000 flu strains since 1940, says the company’s chief scientist Tamar Ben-Yedidia. Racaniello says that, in theory, this combination or proteins should be universal, because every strain of flu would have them.

In a study published in February in the Journal of Clinical Immunology1, BiondVax reported that its Multimeric-001 vaccine was safe and conferred immunity on its own. However, BiondVax thinks that a universal flu vaccine would be a tough sell to regulatory agencies.

Part of the challenge is that the standard test for a vaccine’s efficacy is based on the presence of antibodies to the ever-changing parts of the haemagglutinin protein on the outside of the virus in a vaccinated person's blood. It’s a test their universal vaccine is designed to fail, because Multimeric-001 does not confer immunity to these proteins.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
JPK NanoWizard® Applied to a Wide Range of Research
The NanoWizard® AFM from JPK is applied for interdisciplinary research at the University of South Australia for applications including smart wound healing and how plants can protect themselves from toxins.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Protein Boosts Rice Yield by 54%
Over-expression of a natural protein in rice plants led to a 54% increase in crop yield and 40% increase in nitrogen-use efficiency.
Ice Bucket Challenge Instrumental in Gene Discovery
Donations from the ALS Ice Bucket Chellenge allowed for the largest-ever study of inherited ALS, which identified a new ALS gene.
Genetic Variability in Cell Bank Lots
Researchers working with cancer cells from the same cell bank acquired at the same time, found that the cells were genetically different.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Soil Nitrogen Age Important for Precision Agriculture
Calculating the age of nitrogen in corn and soybean fields could lead to improved fertilizer application techniques.
Targeting Autoimmunity
Researchers have developed a strategy to treat a rare autoimmune disease which could lead to treatments of other autoimmune diseases.
Molecule May Affect Gaucher, Parkinson's Disease
Research has identified a molecule that restores activity of a dysfunctional enzyme linked to Gaucher and Parkinson's disease.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!